BACKGROUND/OBJECTIVES: The objectives were to evaluate the effects of improvement of vitamin D status on biomarkers of oxidative stress (OS) in type 2 diabetic (T2D) subjects and whether vitamin D receptor (VDR)-FokI polymorphisms could modulate the response to vitamin D3 intake. SUBJECTS/METHODS: Subjects with T2D were allocated to one of the two groups to receive either plain doogh (PD; containing 150 mg calcium and no vitamin D/250 ml, n 1 = 50) or vitamin D3-fortified doogh (FD; containing 500 IU/250 ml, n 1 = 50) twice a day for 12 weeks. Outcomes were changes in serum 25-hydroxyvitamin D (25(OH)D), superoxide dismutase, glutathione (GSH), total antioxidant capacity (TAC) and malondialdehyde (MDA). VDR genotypes in 140 T2D subjects in FD were determined by FokI restriction enzyme. RESULTS: After 12 weeks, serum 25(OH)D increased significantly in FD (from 38.5 ± 202.2 to 72.0 ± 23.5, P o 0.001) as compared with PD (from 38.8 ± 22.8 to 33.4 ± 22.8, P = 0.28). Comparisons between FD and PD revealed significant differences in changes of serum MDA (−0.54 ± 0.82 μmol/l vs +0.17 ± 1 μmol/l, P o0.001), GSH (+8.4 ± 40.1 ng/l vs − 13.1 ± 29.4 ng/l, P = 0.002) and TAC (+0.14 ± 0.43 mmol/l vs +0.02 ± 0.45 mmol/l bovine serum albumin equivalent, P = 0.03). Although there was no significant association between FokI genotypes and OS biomarkers, ff variant subgroup showed the weakest response to vitamin D. CONCLUSIONS: Improvement of vitamin D status via daily intake of FD ameliorates OS biomarkers in T2D subjects and the interactive effect of FokI genotypes cannot be ruled out.
INTRODUCTION
There is mounting interest in the role of vitamin D in type 2 diabetes (T2D) and its complications. 1 Cardiovascular disease is the leading cause of morbidity and mortality associated with diabetes. 2 The current global epidemic of T2D highlights the importance of the interaction between genetic and environmental factors including diet. Low-serum 25-hydroxyvitamin D (25(OH)D) concentrations have been shown to correlate with increased risk of a wide range of chronic complications, including cardiovascular disease. 3 The mechanism by which vitamin D deficiency affects cardiovascular health is still unclear. Accumulating evidence indicates that persistent hyperglycemia, by production of excess reactive free radicals, causes oxidative stress (OS), which further augments the development and progression of diabetes and its complications. OS, as an important feature in obesity and diabetes, is linked to the development of adverse metabolic effects, causing dysregulation of adipokines and inflammation. 4 Vitamin D can also have a role in inflammation status through diverse effects on inflammatory cells. 5 Some studies have reported an inverse association between serum concentrations of 25(OH)D and OS biomarkers. [6] [7] [8] Animal studies have shown that vitamin D can modulate activities of the antioxidant enzymes, including catalase, superoxide dismutase (SOD) and glutathione peroxidase (GSH-px) in diabetes. 9 There are interindividual variations in response to vitamin D intake. This heterogeneity in diabetic host responses to vitamin D may partly be explained by variations in the vitamin D receptor (VDR) gene polymorphisms. 10 In our previous study, we showed that diabetic subjects carrying VDR ff genotype may be considered as 'low responders' to vitamin D intake in terms of response of circulating 25(OH)D and certain inflammatory biomarkers. 11 As VDR was found in most of the tissues like pancreatic beta cells, it is supposed that genetic variants of the VDR gene may contribute to the development of T2D. 10 On the other hand, a recent body of evidence indicates a crucial role for OS in the development of diabetes and its later complications including micro-and macro-angiopathy. [12] [13] [14] However, the possible link between VDR polymorphisms and OS has not been investigated to date.
There is a paucity of human randomized controlled trials to assess effects of vitamin D on OS biomarkers in T2D. We conducted a clinical trial on subjects with T2D to evaluate the possible effects of regular intake of vitamin D-fortified Persian yogurt drink (doogh) on diverse aspects of inflammatory, as well as OS biomarkers. The findings on the effects of vitamin D on endothelial and systemic inflammation biomarkers have been reported elsewhere. 5, 11, 15 This study aimed to evaluate the influence of improvement of vitamin D status on some selected markers of OS and to investigate the interactive effect of VDR FokI polymorphism and vitamin D intake on OS biomarkers. We hypothesized that vitamin D supplementation would ameliorate OS, and subjects with different VDR variants might respond differently to vitamin D intake in terms of selected OS biomarkers.
PATIENTS AND METHODS
The protocol of this trial has been published in detail previously. 11 Briefly, this 12-week randomized controlled clinical trial was a part of a larger trial on evaluation of efficacy of vitamin D-fortified doogh according to (VDR) FokI variants ( Figure 1 ). To minimize endogenous vitamin D synthesis, the entire intervention was confined to the cold seasons (fall and winter) of the year. The randomized controlled clinical trial was conducted collaboratively by National Nutrition and Food Technology Research Institute and Tehran University of Medical Sciences in Tehran, the capital of Iran. Trial registration: ClinicalTrials.gov: NCT01236846.
Sample size
On the basis of our previous data on the mean serum 25(OH) D in Iranian diabetic patients (57.8 ± 47.8 nmol/l), 11 to detect a change in mean 25(OH)D of 1 s.d. (effect size of 1) and to have a power of 90%, the calculated sample size was 50 in each group.
Participants
This clinical trial comprised two parts: in the first part (the randomized controlled clinical trial study), the effects of daily intake of two servings of vitamin D3-fortified doogh compared with plain doogh (PD) on OS biomarkers in 100 T2D patients were assessed. In the second part, 140 T2D patients participated in the FD group to assess the possible role of VDR single-nucleotide polymorphisms in response of OS biomarkers to vitamin D intake (the nutrigenetic study). 16 Participants were recruited from the Iranian Diabetes Society and Gabric Diabetes Society members. Volunteers were invited to attend the Laboratory of Nutrition Research at National Nutrition and Food Technology Research Institute while they were fasting. The inclusion criteria were as follows: (a) aged 30-60 years old, (b) willingness to participate and (c) no intake of vitamin, dietary, herbal or omega-3 supplements since at least 3 months prior to the intervention. Exclusion criteria were as follows: (a) history of cardiovascular, gastrointestinal, renal and other endocrinological diseases, (b) pregnancy or lactation, (c) receiving insulin and (d) treatment for weight reduction. Full information on the study design and objectives was given to all participants before they signed a written informed consent form. The study protocol was approved scientifically and ethically by both National Nutrition and Food Technology Research Institute and Tehran University of Medical Sciences.
Interventions, randomization and blinding
A run-in period was considered for 2 weeks during which the subjects were instructed to have a weight maintenance diet according to the American Diabetes Association guidelines including two servings of low-fat dairy products (milk and yogurt), 2-3 servings of fruits and 2-3 servings of vegetables a day. After that participants were randomly assigned to one of the treatment groups of either fortified doogh (containing 170 mg calcium and 500 IU vitamin D3/250 ml; n 2 = 140) or PD (containing 170 mg calcium and no vitamin D/250 ml; n 2 = 50). Participants were instructed to consume a bottle of yogurt drink with both lunch and dinner--that is, 500 ml/d equaling 1000 IU vitamin D3 a day in the FD group. The intervention period was 12 weeks. Every 2 weeks, all subjects were visited for assessment of their compliance and for providing a new package of doogh. To make between-group comparisons of variables, 50 subjects of the FD group were randomly selected. However, comparison of OS biomarkers among three variants of VDR FokI was carried out in the whole population of FD group (n = 140).
After the run-in period, participants were assigned randomly to one of the treatment groups of either fortified doogh (n 1 = 50) or PD (n = 50) using computer-generated random numbers. Letter codes A and B were used to identify two groups, respectively. Yogurt drinks were identical in color, size, taste and packaging. Therefore, participants were not aware of their group, nor were all the interviewers and laboratory staff.
Compliance
Compliance was assessed by checking the consumption tables, counting the empty bottles and direct inquiry both on the biweekly visits and weekly follow-up phone calls.
Quality control of the product The composition (including vitamin D) of dooghs was determined immediately after production, in the middle and at the end of the storage period, to ensure the stability of the components, especially vitamin D, in the product. The measurements were taken at Maad Laboratory of Foods, Drinks and Cosmetics, accredited by the Deputy of Food and Drug of the Iran Ministry of Health.
Main outcomes
The primary outcome was considered to be a significant rise in serum 25(OH)D3 in the FD group. Secondary outcomes were the Patients' characteristics Information on demographic, physical activity, duration of direct sun exposure and smoking habits were gathered using questionnaires and face-to-face interview.
Assessment of dietary intake
To assess whether the changes in the biomarkers were due to the intervention, we assessed dietary intakes. Dietary assessment was performed by employing a 24-h recall questionnaire for 3 days (including a weekend) at the beginning and in the end of the intervention period, as described earlier. 15 To translate dietary intake data to the actual amounts of energy and nutrients, US Department of Agriculture food composition tables with some modifications for Iranian foods were used.
Body composition analysis
To evaluate the percentage of body fat mass (FM), bioelectrical impedance analysis (Quadscan 4000 system, Bodystat, Isle of Man, UK) was employed.
Laboratory investigations
Blood sampling and handling. Blood samples, drawn after 12 h overnight fasting, were divided in two tubes either with or without the anticoagulant, EDTA. The whole blood was used to extract genomic DNA, whereas the sera recovered from clot samples were used for chemical analyses, including OS biomarkers.
Assessment of glycemic status, serum 25(OH)D and OS biomarkers.
Glycemic status and circulating 25(OH)D concentrations were determined as previously described. 17 Fasting serum glucose was determined using the enzymatic method by commercial kits (all from Pars Azmoon, Tehran, Iran) and an auto-analyzer system (Selectra E, Vitalab, Holliston, the Netherlands). Glycated hemoglobin (HbA1c) was determined by the colorimetric method after an initial chromatographic separation (BioSystems, Barcelona, Spain). Insulin resistance was evaluated by the Quantitative Insulin Check Index (QUICKI) calculated as follows 18 QUICKI index: 1/ (log (insulin; μU/ml)+log (glucose; mg/dl)). Serum 25(OH)D3 concentrations were measured by a high performance liquid chromatography method as described elsewhere. 19 The intra-and inter-assay variations were less than 7% and 9%, respectively. To assess OS, we used SOD, GSH, TAC and MDA.
TAC was determined with bovine serum albumin as a standard, as described elsewhere. 20 MDA was assayed as originally described with some minor modifications. 21 Serum concentrations of SOD and GSH were both determined using enzymatic immunoassay (all from Bender Medsystems, Vienna, Austria) with the aid of a microplate reader (StatFax 3200, Awareness, Palm City, FL, USA). VDR analysis. DNA was extracted from anticoagulated blood samples using the Genet Bio DNA Isolation kit (Prime Prep, Chungnam, South Korea) according to the manufacturer's protocol. The VDR genotypes at the FokI single-nucleotide polymorphism site were determined using PCR-restriction fragment length polymorphism analysis, as described previously. 11, 16 Statistical analysis Data were expressed as mean ± s.d. Normal distribution of data was checked using Kolmogrov-Smirnov. Genotype frequencies of FokI were tested for Hardy-Weinberg equilibrium using the χ 2 -test. Repeated-measures analysis of variance was used to evaluate time × group interactions, with time and group as factors. To control confounding factors FM% and QUICKI 22 in between-group comparisons analysis of covariance was employed.
Correlations between changes in OS variables and changes in anthropometrics were evaluated by using the Pearson correlation. In this study, P-value o 0.05 was considered statistically significant. All statistical analyses were performed using the Statistical Package for Social Sciences (SPSS, version 18; Chicago, IL, USA).
RESULTS

Baseline characteristics
Distribution of age, gender and duration of disease and sun exposure did not differ significantly between the two groups and among the genotypic groups (Table 1 ). In our study population, the observed genotype frequency distributions for FokI were in Hardy-Weinberg equilibrium ( Table 1) .
Dietary intakes
Dietary intake data did not show any significant within-or between-group difference. 23 The initial and final values of calcium intake were 595.6 ± 270.0 mg/d versus 530.8 ± 216.4 mg/d, P = 0.140 and 615.5 ± 311.0 mg versus 640.4 ± 315.1 mg, P = 0.66, in FD and PD group, respectively. The initial and final vitamin D intakes, excluding the amount consumed with the fortified dooghs were 15.5 ± 13.7 IU versus 14.1 ± 13.9 IU, P = 0.607 and 17.6 ± 22.0 IU/d versus 16.0 ± 19.0 IU/d, P = 0.670, in FD and PD group, respectively.
Anthropometry and glycemic status
The results of anthropometry and glycemic status were reported previously. 15 The changes of FM (P = 0.07) and body mass index Vitamin D and oxidative stress in diabetes S Shab-Bidar et al (P = 0.23) did not differ significantly between the two groups but the intervention resulted in a significant improvement in fasting glucose (P o 0.001) and QUICKI (P o 0.001) changes ( Table 2) .
Circulating 25(OH)D A significant rise in circulating 25(OH)D was observed as previously reported 15 (+32.6 nmol/l increase in the treatment group versus − 2.7 nmol/l decrease in the control group, P o 0.001; Table 2 ).
Oxidative stress biomarkers
The initial values of OS biomarkers did not show any significant between-group differences ( Table 3) . Repeated-measures analysis of variance revealed a significant time effect (that is, withinsubject difference over time) for MDA (P = 0.004), TAC (P o 0.001) and GSH (P = 0.007) in the FD group, compared with the PD group in which MDA decreased by the end of the intervention, whereas TAC and GSH increased. However, SOD (P = 0.20) did not change within the groups. Time × group interaction was significant for GSH, MDA and TAC (P o 0.001 and P = 0.03 and P = 0.002, respectively). Between-group differences of MDA and GSH were significant after intervention (P o 0.001 and P = 0.018, respectively).The associations were reexamined using analysis of covariance for baseline, FM and QUICKI together as confounders. The difference in TAC was removed after adjustment for FM changes (P = 0.31), whereas remained significant for GSH and MDA changes (P o 0.001 and P = 0.001, respectively). In addition, significant differences after adjustment for QUICKI were disappeared for TAC (P = 0.11), whereas remained for GSH and MDA (P o 0.001 and P = 0.001, respectively; Table 3 ). A significant inverse association was found between changes in GSH and changes in FM (r = − 0.23, P = 0.032).
Host response
Among 140 T2D patients, the time effect was insignificant for SOD (P = 0.72), whereas improvement of vitamin D status was accompanied by amelioration and a significant time effect in MDA (Po 0.001), TAC (Po 0.001) and GSH (P = 0.027; Table 3 ). Serum MDA concentrations significantly decreased in both FF (P = 0.006) and Ff (P = 0.001) subgroups and TAC increased only in FF (P = 0.003). However, time × group interaction was not statistically significant for either of the OS biomarkers through FokI genotypes (p for trend40.05 for all; Table 4 ).
DISCUSSION
In the present investigation, we observed a significant increase in 25(OH)D concentration due to the intervention, as there were no significant between-group difference in either dietary intake or duration of sun exposure. The improvement of vitamin D status was followed by significant improvements in glycemic status, FM, TAC, GSH and MDA levels in T2D subjects of FD group compared with CD group after 12 weeks. There were no significant differences in the diabetic host response to intake of vitamin D according to FokI VDR variants in terms of OS biomarkers.
Antioxidant action of vitamin D is among the newest proposed non-calcemic functions of this compound. Having a similar structure to cholesterol has led to a hypothesis that vitamin D may be an antioxidant. 24 Later in a study, antioxidant properties of vitamin D were found equal or even more than vitamin E. 25 Recently, increased concentration of glycation advanced end products and OS biomarkers in experimental diabetes and amelioration of these markers following vitamin D supplementation has been reported in a rat model. 26 Moreover, it was shown that the active form of vitamin D, 1,25(OH)D, reflects pleiotropic action on target genes in different types of cancer cells, which regulate common cellular process including OS. 27 Production of reactive oxygen species (ROS) induces peroxidation of membrane fat. MDA is a by-product of fat peroxidation. 28 According to the presence of inflammation in T2D, these patients are prone to increased level of lipid peroxidation products. 29, 30 Vitamin D and oxidative stress in diabetes S Shab-Bidar et al Vitamin D intake decreased MDA after 12 weeks' consumption of FD. In some cross sectional studies, a correlation between vitamin D deficiency and augmented fat per oxidation was reported. 31, 32 Moreover, supplementation with a vitamin D analog, α-calcidiol, resulted in amelioration of OS biomarkers in patients with juvenile idiopathic arthritis. 33 In another study, supplementation with 50 000 IU/day vitamin D was accompanied by a significant decrease in serum MDA in nonalcoholic fatty liver disease patients. 34 Current findings are supportive of early cell culture studies that reported vitamin D-mediated decreased lipid peroxidation and proposed vitamin D as a membrane antioxidant. 35 It is reported that both glycemic index and glycemic load, independent of carbohydrate content of diet, directly correlate with MDA concentrations. 36 The combined effect of persistent hyperglycemia and poor dietary habits can exacerbate OS, which in turn will potentially precipitate further complications. During run-in period of this study, we instructed all participants to follow a healthy diet, according to the American Diabetes Association guidelines, for weight maintenance to minimize the effect of diet on OS biomarkers. Dietary assessment revealed no significant within-or between-group differences; therefore, the improvement of glycemic and OS markers only in the FD group can be attributed to vitamin D intake. Decreased serum GSH in diabetic patients compared with the healthy controls has already been reported. 37, 38 The enzymatic redox system of GSH is the most important intracellular defense against ROS. In poorly controlled diabetes, the GSH-dependent antioxidant enzymes are susceptible to oxidation. 39 The resulting augmented OS has been associated with the increased production of inflammatory cytokines, including adipokines, from adipose tissue, which may increase GSH utilization. 40 The inverse relationship of body FM and GSH in T2D has been reported previously. 38 In the current study, GSH concentration increased in response to vitamin D-fortified doog intake. There are limited data on the effects of vitamin D intake on OS biomarkers. Reports from animal studies suggest that vitamin D in its active form can regulate the synthesis of the GSH level. 25, 31 Moreover, it was shown that vitamin D3 is effective to increase GSH level by almost 50%. 25 The stimulatory effect of vitamin D upon GSH synthesis has been recently observed in cellular as well as human studies. 41, 42 Vitamin D can increase GSH synthesis through upregulation of gamma glutamyl transpeptidase. 43, 44 In addition, vitamin D may have an antioxidant role in the brain by inhibiting the synthesis of inducible nitric oxide synthase and increasing levels of the antioxidant GSH. 31 The beneficial antioxidative effects of vitamin D supplementation may be mediated by an improvement in the cellular GSH levels and a decrease in ROS and pro-inflammatory cytokines. 41 Evidence from clinical trials is scarce. In a study on the effects of daily supplementation with 50 000 IU vitamin D for 6 weeks in pregnant women with gestational diabetes mellitus, both TAC and total GSH increased significantly in the treatment group as compared with the placebo group. 45 Oxidative stress and inflammation are intertwined entities: augmentation or attenuation of one may affect the other. [46] [47] [48] [49] Both OS and inflammation are features of obesity and diabetes. 47, 48 We have previously reported the glycemic optimizing and antiinflammatory effects of vitamin D. 5, 15 In the current study, however, persistence of between-group significant difference in changes of GSH and MDA after controlling for QUICKI indicates an independent effect of vitamin D on antioxidant defense arm.
Diabetic patients, compared with nondiabetic healthy subjects, are expected to have lower SOD activity at the vascular matrix. It has been hypothesized that this may have some role in the increased susceptibility of diabetic vascular cells to the superoxide anions in extracellular spaces. 50 Increased expression of SOD during inflammation and OS is a cellular defense mechanism to deactivate excessively produced reactive oxygen species. 51 Therefore, with attenuation of OS, SOD expression is expected to Table 4 . Comparisons of the variables among the FokI genotypic groups with T2D before and after 12 weeks' intervention in the nutrigenetic study between-group comparison after 12 weeks; P 3 for trend: between-group comparison of changes after 12 weeks.
Vitamin D and oxidative stress in diabetes S Shab-Bidar et al decrease. Findings from the current study showed that the intake of vitamin D did not affect serum SOD concentrations in T2D patients. Decreased SOD activity following 3-month treatment with 1 μg/d α-calcidiol has already been reported in adolescent subjects with juvenile idiopathic arthritis. 33, 52 The increase in circulating 25(OH)D concentration was associated with a significant increase in TAC after 12 weeks in FD, compared with the PD group. This finding is in the same line of evidence reported earlier. 45 Persistent hyperglycemia may induce OS via several mechanisms. Therefore, glycemic control can theoretically contribute to OS attenuation. Our finding of disappearance of significant between-group difference in TAC following adjustment for QUICKI indicates the glycemic statusmediated effect of vitamin D on TAC.
An association between blood glucose and OS 53, 54 and the link between VDR FokI variants and fasting serum glucose 11, 55 have already been reported. Jain et al. 55 observed that the FokI Ff genotype showed a significantly greater improvement in insulin sensitivity compared with women with the FokI FF genotype. However, they did not assess the effect of treatment with vitamin D on OS biomarkers. We previously found that T2D subjects with VDR ff genotype may be regarded as 'low responders' to vitamin D intake in terms of response of circulating 25(OH)D and certain inflammatory biomarkers. In the current study, no association between the selected OS markers and FokI polymorphisms was observed. However, significant within-group changes of MDA in both FF and Ff and of TAC only in FF further support our previously reported finding of 'low-responsiveness' of ff variant to vitamin D supplementation. 5 This finding does not rule out the possible effect of the host genetic makeup on antioxidant potency. Some evidence indicates of differential influence of VDR polymorphism, like BsmI and TaqI, on disease outcomes, notably cancers. 56 The possible effect of endogenous antioxidant polymorphisms cannot be neglected. 57 Some limitations to this study should be acknowledged. The intervention was conducted just for 12 weeks. The results of this study, therefore, should be supported by further studies with longer durations. Moreover, only one dose of vitamin D was tested, and the possible association of other VDR polymorphisms with OS markers was not investigated.
CONCLUSIONS
In conclusion, the results of this randomized controlled trial in T2D suggest that consumption of a vitamin D-fortified doogh may improve vitamin D status and attenuate OS. In addition, we concluded that the VDR FokI genotypes may be involved in OS response to vitamin D-fortified doogh intake in diabetic host. These findings can potentially have preventive implications against the late diabetic complications.
